. Initial rates of reactions with various ratios of 1a and isobutyraldehyde. Reactions were performed in triplicate. 49 ± 2 59 ± 1 1.2 6.0 43 ± 0.2 56 ± 2 1. 3  Table S2 . Relative reaction rates of indoles 1a and 20 with isobutyraldehyde. Solutions containing 1 mM 1a, 20, and isobutyraldehyde in D 2 O were incubated at room temperature in 100 mM sodium phosphate buffer. Conversions were assessed by 1 H NMR spectroscopy after isobutyraldehyde was fully consumed. (A 440 ) showing hydrolysis of 1 µM 5a and 5b in 5 mM sodium acetate pH 4.50 at room temperature. Compound 4 was synthesized independently and the intensity of its chromatograph is arbitrarily scaled. Samples were analyzed using a gradient of 5 to 95% acetonitrile in H 2 O with 0.1 % trifluoroacetic acid. 
Fig. S4. Liquid chromatographs

II. Materials and methods
A. General synthetic methods
All reagents were obtained from Sigma-Aldrich, Acros, or TCI and used without further purification. Anhydrous solvents were dried and deoxygenated by purification through columns of alumina and Q-5 (1), with the exception of N,N-dimethylformamide, which was purchased in a sealed bottle and stored over molecular sieves. Deuterated solvents were purchased from Cambridge Isotope Laboratories. Solvents were removed on a Buchi Rotavapor R-114 equipped with a Welch 2026 self-cleaning dry vacuum pump or with an Edwards RV3 vacuum pump.
Thin layer chromatography was performed with Silicycle 60 Å silica gel plates and analyzed by UV illumination or I 2 staining. Flash chromatography was performed with Silicycle 60 Å 230-400 mesh silica gel. High-pressure liquid chomatography was performed on a Varian ProStar instrument with a UV absorption detector operating at 210 and 254 nm. Preparative-scale HPLC was performed on a 100 Å C18 reverse phase column (250 x 21.4 mm) with a solvent flow rate of 20 mL/min, or a Varian Microsorb 300-5 C4 reverse phase column (250 x 4.6 mm) with a solvent flow rate of 1 mL/min. NMR spectra were acquired on Bruker AVQ-400, AVB-400, DRX-500, AV-500, or AV-600 spectrometers. 1 H NMR spectra were referenced to residual CHCl 3 (7.26 ppm), CD 2 HCN (1.94 ppm), or CD 2 HOD (3.31 ppm).
13 C NMR spectra were referenced to CDCl 3 (77.16 ppm), CD 3 CN (1.32 ppm), or CD 3 OD (49.00 ppm). NMR spectra were processed using MestReNova (Mestrelab Research S.L.). High-resolution ESI mass spectra of small molecules were obtained at the UC Berkeley Mass Spectrometery Facility on a Thermo LTQ Orbitrap mass spectrometer.
B. Synthesis of new compounds 2-(((tert-butyldimethylsilyl)oxy)methyl)-1H-indole (6):
An oven-dried flask was charged with indole-2-methanol (1.581 g, 10.74 mmol), TBSCl (1789 g, 11.87 mmol, 1.10 equiv), and imidazole (2.197 g, 32.27 mmol, 3.00 equiv), and this mixture was suspended in CH 2 Cl 2 (40 mL, anhydrous). After 16 h, the reaction mixture was concentrated to an orange residue. The crude mixture was taken up in Et 2 O (50 mL), washed with aqueous AcOH (5% v/v, 3 x 50 mL) and brine (25 mL). The combined organic layers were dried over sodium sulfate and concentrated to a crystalline solid (2.789 g, 10.67 mmol, 99%) which was used without further purification. R f = 0.5 in 9:1 hexanes:EtOAc. 
methyl 3-(2-(hydroxymethyl)-1H-indol-1-yl)propanoate (2):
To a solution of 7 (1.283 g, 3.692 mmol) in tetrahydrofuran (20 mL) at 0 °C was added tetrabutylammonium fluoride (1.0 M in THF, 3.90 mL, 3.90 mmol, 1.06 equiv). After 15 minutes, the reaction mixture was diluted with diethyl ether (20 mL) and washed with NaHCO 3 (sat. aq., 3 x 20 mL), and concentrated to a pale green oil. The oil was purified by silica gel chromatography (2:1 hexanes:EtOAc, R f = 0.25) to yield a white crystalline solid (822 mg, 3.524 mmol, 95% 
2-(trimethylsilyl)ethyl methyl((1-(3-oxo-3-((3-(3-(2-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)acetamido)propoxy)propyl)amino)propyl)-1H-indol-2-yl)methoxy)carbamate (12):
To an oven-dried flask charged with 3 (6.5 mg, 17 µmol) and diisopropylethylamine (9.0 µL, 51 µmol, 3.0 equiv) in CH 2 Cl 2 (1 mL, anhydrous) at 0 °C was added pentafluorophenyl trifluoroacetate (3.0 µL, 17 µmol, 1.0 equiv). The solution was allowed to warm to room temperature over the next 30 min, after which it was filtered through a 0.5 cm 3 silica plug which was washed with CH 2 Cl 2 (2 mL). The filtrate was concentrated and dissolved in N,N-dimethylformamide (3 x 0.5 mL, anhydrous), then added to a solution of biotin-PEG 3 -NH 2 (7.7 mg, 17 µmol, 1.0 equiv) and diisopropylethylamine (9.0 µL, 51 µmol, 3.0 equiv) in N,N-dimethylformamide (0.5 mL, anhydrous). After 24 h, the solution was concentrated and then purified by silica gel chromatography (8% MeOH in CH 2 Cl 2 , R f = 0.1), affording a white solid (10.2 mg, 12.4 µmol, 75%). 
3-(2-(((methylamino)oxy)methyl)-1H-indol-1-yl)-N-(3-(3-(2-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)acetamido)propoxy)propyl)propanamide (1b):
To an oven-dried flask charged with 12 (2.2 mg, 2.7 µmol) and CsF (6.5 mg, 43 µmol, 16 equiv) was added N,N-dimethylformamide (0.5 mL, anhydrous). After 2 h, H 2 O (1 mL) and MeOH (1 mL) were added and the reaction mixture was concentrated to a white residue. The crude product was purified by silica gel chromatography (65:20:20:2.5:2. To an oven-dried flask charged with 3 (9.8 mg, 25 µmol) and diisopropylethylamine (13 µL, 75 µmol, 3.0 equiv) in CH 2 Cl 2 (1 mL, anhydrous) at 0 °C was added pentafluorophenyl trifluoroacetate (4.5 µL, 26 µmol, 1.0 equiv). The solution was allowed to warm to room temperature over the next 45 min, after which it was filtered through a 0.5 cm 3 silica plug which was washed with CH 2 Cl 2 (2 mL). The filtrate was concentrated and dissolved in N,N-dimethylformamide (2.0 mL, anhydrous). To 200 µL of this solution was added diisopropylethylamine (4.5 µL, 26 µmol, 17 equiv) and a solution of AF488 cadaverine (1.0 mg, 1.6 µmol) in N,N-dimethylformamide (1.0 mL, anhydrous). After 21 h, MeOH (1 mL) was added and the reaction mixture was concentrated to a red residue which was purified by HPLC on a C18 column (time (min), % acetonitrile in H 2 O: 0, 10; 5, 10; 35, 100). The product was isolated as a red powder (1.17 mg, 1.15 µmol, 74% 
5-methoxy-indole
-2-methanol (14) was prepared as previously described (2). 1 H NMR (600 MHz, CDCl 3 ) δ 8.36 (s, 1H), 7.14 (d, J = 8.8 Hz, 1H), 7.03 (d, J = 2.4 Hz, 1H), 6.83 (dd, J = 8.7, 2.5 Hz, 1H), 6.30 (d, J = 2.5 Hz, 1H), 4.69 (s, 2H), 3.83 (s, 3H), 2.64 (s, 1H). 13 C NMR (151 MHz, MeOD) δ 155.1, 140.5, 133.4, 130.1, 112.5
methyl 3-(2-(hydroxymethyl)-5-methoxy-1H-indol-1-yl)propanoate (17):
A solution of 16 (1.59 g, 4.21 mmol) in tetrahydrofuran (20 mL) was cooled to 0°C, followed by the addition of tetra-n-butylammonium fluoride (1.0 M in tetrahydrofuran, 4.50 mL, 4.50 mmol, 1.07 equiv). After 1 h, the reaction mixture was diluted with Et 2 O (40 mL), washed with NaHCO 3 (3 x 20 mL, sat. aq.) and brine (30 mL), dried over Na 2 SO 4 , filtered and concentrated. The residue was purified by silica gel chromatography to give 17 as a white crystalline solid (1.04 g, 3.95 mmol, 94%). R f = 0.13 in 2:1 hexanes:EtOAc. 
3-(5-methoxy-2-(3,8,8-trimethyl-4-oxo-2,5-dioxa-3-aza-8-silanonyl)-1H-indol-1-yl)propanoate (18):
An oven-dried flask was charged with 17 (330 mg, 1.25 mmol), carbamate 8 (300 mg, 1.57 mmol, 1.25 equiv), and 1,1′-(azodicarbonyl)dipiperidine (317 mg, 1.26 mmol, 1.01 equiv). The flask was purged with nitrogen and the solids were dissolved in toluene (30 mL, anhydrous). Tributylphosphine (313 µL, 1.25 mmol, 1.00 equiv) was added, resulting in the formation of a precipitate. After 2 h, the reaction mixture was diluted with Et 2 O (30 mL), washed with H 2 O (2 x 50 mL) and brine (50 mL), dried over Na 2 SO 4 , filtered and concentrated. The residue was purified by silica gel chromatography to give 18 as a colorless oil (242 mg, 554 µmol, 44%). R f = 0.5 in 2:1 hexanes:EtOAc. 
3-(5-methoxy-2-(3,8,8-trimethyl-4-oxo-2,5-dioxa-3-aza-8-silanonyl)-1H-indol-1-yl)propanoic acid (19):
To a solution of 18 (84.9 mg, 194 µmol) in dioxane (5 mL) was added a freshly prepared aqueous solution of LiOH (0.5 M, 780 µL, 390 µmol, 2.01 equiv). After 3 h, the reaction was quenched with the addition of AcOH (5% v/v aqueous solution, 2.5 mL). The solution was extracted with ethyl acetate (3 x 40 mL) and the combined organic layers were concentrated and purified by silica gel chromatography to give 19 as a light yellow oil (65.8 mg, 156 µmol, 80% 3-(5-methoxy-2-(((methylamino)oxy)methyl)-1H-indol-1-yl)propanoic acid (20): A flask was charged  with 19 (59.8 mg, 141 µmol) and CsF (100 mg, 658 µmol, 4.67 equiv) under nitrogen, followed by the addition of N,N-dimethylformamide (4 mL, anhydrous) . After 20 h, H 2 O (4 mL) was added and the solution was concentrated. The residue was purified by silica gel chromatography to give 20 as a colorless oil (39.0 mg, 140 µmol, 99% 3-(1-isopropyl-8-methoxy-2-methyl-1,2-dihydro-[1,2]oxazino[5,4-b]indol-5(4H)-yl)propanoic acid (21) : To a solution of 20 (18 mg, 65 µmol) in methanol (2 mL) was added isobutyraldehyde (9.0 µL, 99 µmol, 1.5 equiv). After 1 h, the reaction mixture was concentrated to a yellow oil (21.3 mg, 64.1 µmol, 99% ). R f = 0.6 in 1:1 hexanes:EtOAc with 2% AcOH. 5-((3,3-diethoxypropyl)carbamoyl)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (22) : To a mixture of 5-carboxyfluorescein (30 mg, 80 µmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (31 mg, 162 µmol, 2.0 equiv), and 1-hydroxybenzotriazole hydrate (20 wt% H 2 O, 55 mg, 326 µmol) was added N,N-dimethylformamide (3 mL) followed by triethylamine (22.2 µL, 159 µmol, 2.0 equiv) and 3-aminopropionaldehyde diethyl acetal (13 µL, 80 µmol, 1.0 equiv). After being stirred in the dark for 26 h, MeOH (1 mL) was added and the solution was concentrated to an orange oil which was purified by silica gel chromatography (8% MeOH in CH 2 CD 3 OD) δ 170.7, 168.3, 162.4, 155.5, 154.4, 137.9, 135.0, 130.3, 129.5, 126.1, 125.0, 114.2, 111.2 
5-((3-((benzyloxy)imino)propyl)carbamoyl)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (5a):
A mixture of 4 (3.2 mg, 7.4 µmol) and O-benzylhydroxylamine hydrochloride (1.3 mg, 8.1 µmol, 1.1 equiv) was dissolved in 1:1 aqueous sodium acetate (100 mM, pH 4.50) : MeOH (1 mL). After 2.5 h, the resulting suspension was concentrated to an orange solid that was purified by HPLC on a C18 column (time (min), % MeCN in H 2 O: 0, 40; 5, 40; 15, 55), affording an orange solid (3.2 mg, 6.0 µmol, 81%). The product was isolated as a mixture of syn:anti isomers in a 9:11 ratio. (5-(2-carboxyethyl)-2-methyl-1,2,4,5-tetrahydro-[1,2]oxazino[5,4-b]indol-1-yl) ethyl)carbamoyl)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (5b): A mixture of 4 (3.2 mg, 7.4 µmol) and 1a (2.0 mg, 8.1 µmol, 1.1 equiv) was dissolved in 1:2 aqueous sodium acetate (100 mM, pH 4.50) : MeOH (1.5 mL). After 2.5 h, the reaction mixture was concentrated to an orange solid that was purified by HPLC on a C18 column (time 
5-((2-
O. Deuterated sodium phosphate buffers were prepared by combining 100 mM solutions of phosphoric acid-d 3 in D 2 O and Na 3 PO 4 in D 2 O to the appropriate pD. For determination of the order of each reactant in the rate equation, stock solutions containing 1a (1.5 mM or 3.0 mM) or isobutyraldehyde (1.5 mM or 3.0 mM) in deuterated buffer solution were combined in a 1:1 ratio immediately before NMR acquisition. For determination of rate constants, stock solutions containing 1a (1 mM) or isobutyraldehyde (1 mM) in deuterated buffer solution were combined in a 1:1 ratio immediately before NMR acquisition (stock solutions containing 1.5 mM of each reactant were used at pD 7.0). All kinetic data were acquired on a Bruker AV-500 or AV-600 spectrometer with the probe temperature maintained at 295 K. 8-spectrum scan sets were acquired every 30 s, and all reactions were followed for at least one half-life. The disappearance of the N-CH 2 resonance was followed over time and the methyl resonances of the product were integrated to determine the total amount of material in solution. Data was analyzed in MestReNova and Microsoft Excel. Relative reaction kinetics of unsubstitued and methoxylated indoles: A stock solution of 3-(trimethylsilyl)-2,2',3,3'-tetradeuteropropionic acid (1 mM) in deuterated sodium phosphate buffer (100 mM, pD 4.5 or 6.0) in D 2 O was used to make 3 mM solutions of isobutyraldehyde and indoles 1a and 20. Both indoles were mixed in a 1:1 ratio and their concentrations were verified by 1 H NMR. The solution of isobutyraldehyde was added to the indole mixture to give the reactants in a final ratio of 1:1:1. The resulting solution was incubated at room temperature until the isobutyraldehyde was fully consumed. The conversion of each indole to the corresponding oxacarboline product was assessed by integrating the N-CH 2 resonances of 1a, 20, 10, and 21. Experiments were carried out in triplicate on a Bruker AV-600 spectrometer. Small molecule hydrolysis: Hydrolysis solutions contained 1 µM 5a or 5b, 25 µM phenylalanine as an internal standard, and 5 mM sodium acetate at the appropriate pH. The solutions were incubated at room temperature and 50 µL aliquots were repeatedly analyzed by liquid chromatography on an Agilent 1200 instrument using an Agilent Poroshell 120 EC-C18 reverse phase column (4.6 x 50 mm) with a solvent flow rate of 0.4 mL/min. The following gradient was employed (time (min), % MeCN in H 2 O with 0.1% TFA): 0, 5; 10, 95; 12, 95; 14, 5; 19, 5. The time of the first injection for each solution was assigned as t = 0. Integrals of the absorption peaks for 5a and 5b at 440 nm were normalized against the phenylalanine peak for each injection.
D. Biotinylation of glyoxyl-Mb
Preparation of glyoxyl-Mb: Transamination of horse heart myoglobin (Sigma-Aldrich) was performed following a modified literature protocol (4). Stock solutions of myoglobin (50 µM) in sodium phosphate buffer (25 mM, pH 6.50) and pyridoxal 5'-phosphate (PLP, 200 mM) in sodium phosphate buffer (25 mM, pH adjusted to 6.50) were prepared. The myoglobin solution was combined with an equal volume of the PLP stock solution or vehicle (25 mM sodium phosphate, pH 6.50) and incubated at 37 °C for 1 h in the dark. The solutions were then diluted 10-fold and exchanged into sodium phosphate buffer (25 mM, pH 6.50) 5 times using centrifugal concentrators (Amicon Ultra, 10 kDa MWCO), and then dialyzed against sodium phosphate buffer (10 mM, pH 6.50) to remove residual pyridoxal phosphate. Time-dependent labeling: Glyoxyl-Mb or Mb (3 µg) and 1b or N-(aminooxyacetyl)-N'-(D-biotinoyl) hydrazine (aminooxy-biotin) (250 µM) were combined in sodium acetate buffer (25 mM, pH 4.00) in a 4 µL reaction volume at 37 °C for 0-120 min and then quenched with benzaldehyde (10 mM). Concentration-dependent labeling: Glyoxyl-Mb or Mb (3 µg) and 1b or aminooxy-biotin (0-200 µM) were combined in sodium acetate buffer (100 mM, pH 4.00) in a 4 µL reaction volume at 37 °C for 3 h and then quenched with benzaldehyde (10 mM). pH-dependent labeling: Glyoxyl-Mb or Mb (1.7 µg) and 1b or aminooxy-biotin (250 µM) were combined in sodium acetate (100 mM, pH 4.00-5.50) or sodium phosphate (100 mM, pH 6.00-7.50) buffer in a 4 µL reaction volume at 37 °C for 3 h and then quenched with benzaldehyde (10 mM). Co-treatment with BnONH 2 : Glyoxyl-Mb or Mb (1.7 µg), 1b (100 µM), and BnONH 3 Cl (0-800 µM) were combined in sodium acetate buffer (100 mM, pH 4.50) in a 5 µL reaction volume at 37 °C for 3 h and then quenched with benzaldehyde (10 mM). Co-treatment with aniline: Glyoxyl-Mb or Mb (1.7 µg), 1b (100 µM), and anilinium acetate (0-50 mM, pH 4.50 or 5.50) or anilinium phosphate (0-50 mM, pH 6.50) buffer were combined in sodium acetate buffer (50 mM, pH 4.50 or 5.50) or sodium phosphate buffer (50 mM, pH 6.50) in a 10 µL reaction volume at 37 °C for 4 h and then quenched with benzaldehyde (10 mM). General procedure for Western blots: Reaction mixtures were incubated for 5 min at room temperature after addition of benzaldehyde, then combined with 33% (v/v) 4x SDS loading buffer with β-mercaptoethanol and run on a 26-well Bio-Rad Criterion XT 4-12% bistris gel (45 min, 175 V) in XT MES buffer. The contents of the gel were then wet-transferred to nitrocellulose membranes in trisglycine buffer with 20% MeOH (60 min, 100 V) and total protein loading was imaged with Ponceau S stain (0.1% w/v in 5% v/v acetic acid). The blots were then blocked overnight at 4 °C in phosphate-buffered saline with 0.1% Tween-20 (PBST) containing bovine serum albumin (4% w/v). The blot in blocking solution was then incubated with mouse α-biotin FITC (Jackson ImmunoResearch, 1/10000) for 1h at room temperature, washed with PBST (3 x 10 min), and imaged. Western blots were scanned on an Amersham Typhoon 9410 imager and data were analyzed in ImageJ.
E. Preparation and evaluation of FGly-MBP conjugates
FGly-MBP and MBP C390A were prepared as previously described (5) . ESI-MS of full-length protein conjugates: Conjugation reactions of MBP for mass spectrometry analysis were prepared by combining FGly-MBP or MBP C390A (6.8 µg) with 1a or L-tryptophan methyl ester (1 mM) in sodium acetate buffer (100 mM, pH 5.0) in a 8 µL reaction volume at 37 °C for 12 h. The reactions were then quenched by addition of dibasic sodium phosphate (100 mM, 92 µL) to bring the pH to 7.9, and stored at 4 °C for less than 1 h prior to analysis by ESI-MS.
Tryptic digest: A conjugate of FGly-MBP with 1a (5.7 µg) in sodium phosphate buffer (65 mM, pH 7.2) was incubated with dithiothreitol (DTT, 2.54 mM, 60 nmol) at 56 °C for 30 min, iodoacetamide (5.98 mM, 150 nmol) at room temperature for 1 h in the dark, and then DTT (2.33 mM, 60 nmol) at room temperature for 5 min (although no cysteine residues are present in FGly-MBP, DTT and iodoacetamide were added to show that the oxacarboline moiety is compatible with standard reduction and alkylation procedures employed in proteolytic digestion). The resulting sample was treated with trypsin (0.115 µg, 2 wt%) at 37 °C for 18 h. The solution was then acidified with formic acid to a final concentration of 1% and purified on Millipore ZipTip C18 resin, eluting with a solution of 70% MeCN and 1% formic acid in H 2 O. The eluant was concentrated by centrifugal evaporation and the resulting residue was resuspended in water prior to analysis at the UC Berkeley HHMI Mass Spectrometry Lab by flow injection on a Bruker Apex-Qe ESI-Q-FT-ICR mass spectrometer (9.4T). HRMS (ESI) calcd for C 45 H 70 N 13 O 15 [M+H] + : 1032.5114; found: 1032.5220. Thrombin cleavage: A solution of FGly-MBP (44 µg) was labeled with AF488 C 5 -aminooxyacetamide or 1c (200 µM) in sodium acetate buffer (100 mM, pH 4.5) in a 20 µL reaction volume at 37 °C for 17 h. The solutions were diluted 10-fold and exchanged into PBS 5 times using a centrifugal concentrator (Amicon Ultra, 30 kDa MWCO). Solutions of the resulting AF488-MBP conjugates (0.6 µg) in PBS were incubated with thrombin (0-1.2 U) in a 6 µL reaction volume at 37 °C for 1 h and then quenched by addition of reducing SDS loading buffer and boiling for 5 min prior to resolution by SDS-PAGE. The gel was imaged and then stained with Colloidal blue (Life Technologies). Fluorescence polarization: Oxime and oxacarboline-linked AF488-MBP conjugates were prepared as described above. Amide-linked AF488-MBP was prepared by treatment of FGly-MBP (44 µg) with AF488 5-SDP ester (500 µM) in sodium bicarbonate buffer (100 mM, pH 8.0) in a 15 µL reaction volume at 37 °C for 45 min. The solution was then diluted 10-fold and exchanged into PBS 5 times using a centrifugal concentrator (Amicon Ultra, 30 kDa MWCO). After evaluating conjugation efficiency by UV-vis, solutions of each conjugate containing 100 nM AF488 were prepared in PBS (100 µL) in triplicate. The solutions were incubated in a sealed black 96-well plate (Costar) at 37 °C. Fluorescence polarization data were acquired periodically using a Perkin Elmer Victor 3 V plate reader. After nearly one week, the plate reader was equilibrated to 37 °C, thrombin (12 U) was added to each well, and polarization was monitored at 12 min intervals. Solutions of the free fluorophores (100 nM) exhibited polarization values of 40 ± 1.3 mP (AF488 C 5 -aminooxyacetamide) and 104 ± 0.3 mP (1c), consistent with those of the thrombin-cleaved products, with error attributable to the presence of a mixture of a peptide-AF488 conjugate and free fluorophore, as well as a slight increase in the concentration of AF488 conjugate solutions due to evaporation of PBS over the course of a week at 37 °C.
F. Preparation and evaluation of AF488-α-HER2
FGly-α-HER2 was prepared as previously described and Cys to FGly conversion was 97% complete (6).
Preparation of AF488-α-HER2:
FGly-α-HER2 (76 µg) was incubated with 1c (1 mM) in sodium acetate buffer (100 mM, pH 4.50) in a 100 µL reaction volume at 37 °C for 12 h. The solution was then diluted 10-fold and exchanged into PBS 6 times using a centrifugal concentrator (Amicon Ultra, 30 kDa MWCO). The conjugation efficiency was determined on a Thermo NanoDrop 2000 spectrophotometer, using ε 280 = 210000 M -1 cm -1 for FGly-α-HER2, ε 494 = 71000 M -1 cm -1 for AF488, and applying a correction factor to account for absorption of AF488 at 280 nm (ε 280 = ε 494 * 0.11). Cell culture: SKOV3 and Jurkat T cells were obtained from ATCC and grown in a humidified 5% CO 2 atmosphere at 37 °C in RPMI-1640 media supplemented with glutamine, 10% fetal bovine serum, and penicillin/streptomycin. Cell density was kept between 1x10 5 and 2x10 6 cells/mL. Live cell labeling with AF488-α-HER2: Cells in culture media were harvested and washed with FACS buffer (1 % fetal bovine serum in PBS) and resuspended at 10 6 /mL in FACS buffer in 100 µL aliquots in a 96-well V-bottom plate (Costar), then cooled to 4 °C (all subsequent manipulations were performed at 4 °C). Labeling experiments were performed in triplicate. All antibody incubations were carried out in 100 µL FACS buffer, and all washing steps entailed centrifugation at 300 
